GlassScriptPhysician profile
Charmaine Grant
NPI 1659921625
$2,376.59
in general payments reported to CMS, 2019-2025
37 companies · $1,001 in 2025
The $1,001 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $59.33 · 2022: $27.08 · 2023: $333 · 2024: $957 · 2025: $1,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,277 · Education: $13.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,277.14 |
| Education | $13.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $284.49 | 2023-2025 | Reblozyl, Pomalyst |
| Genentech USA, INC. | $163.34 | 2021-2025 | Tecentriq, Polivy, Lunsumio |
| Astrazeneca Pharmaceuticals LP | $158.55 | 2024-2025 | Lynparza, Tagrisso, Enhertu |
| Incyte Corporation | $152.58 | 2023-2025 | Jakafi, Monjuvi |
| Pfizer INC. | $133.88 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $124.98 | 2023 | Xpovio |
| Novartis Pharmaceuticals Corporation | $124.57 | 2024-2025 | |
| Janssen Biotech, INC. | $121.18 | 2024-2025 | Talvey, Tecvayli, Darzalex |
| Eisai INC. | $89.98 | 2024-2025 | |
| Genzyme Corporation | $88.95 | 2024-2025 | |
| Daiichi Sankyo INC. | $86.22 | 2025 | Vanflyta, Datroway, Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $80.32 | 2023-2024 | Iclusig |
| Bayer Healthcare Pharmaceuticals INC. | $79.34 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $62.65 | 2024-2025 | Ultomiris |
| Glaxosmithkline, LLC. | $53.30 | 2023-2024 | Ojjaara |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $51.55 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Abbvie INC. | $47.30 | 2024 | |
| Array Biopharma INC | $46.20 | 2025 | Braftovi, Tukysa, Mektovi |
| Tersera Therapeutics LLC | $31.48 | 2024 | Zoladex |
| Caris Mpi, INC. | $29.06 | 2025 | Mi Cancer Seek |
| Otsuka America Pharmaceutical, INC. | $27.08 | 2022 | |
| Coherus Oncology, INC. | $26.08 | 2023 | |
| Blueprint Medicines Corporation | $25.72 | 2024 | Ayvakit |
| Geron Corporation | $24.87 | 2025 | Rytelo |
| G1 Therapeutics, INC. | $24.30 | 2023 | Cosela |
| Beigene USA, INC. | $24.24 | 2024 | Brukinsa |
| Acrotech Biopharma INC. | $23.25 | 2023 | Beleodaq |
| Immunocore Limited | $22.76 | 2025 | Kimmtrak |
| Exelixis INC. | $22.67 | 2024 | Cabometyx |
| Immunogen, INC. | $21.65 | 2024 | Elahere |
| Lilly USA, LLC | $20.85 | 2024 | Verzenio |
| E.R. Squibb & Sons, L.L.C. | $20.25 | 2024 | |
| Verity Pharmaceuticals INC. | $18.81 | 2023 | Trelstar |
| Novocure INC. | $18.04 | 2025 | Optune Lua (Novottf-200t) |
| Deciphera Pharmaceuticals INC. | $17.83 | 2024 | Qinlock |
| Myriad Genetic Laboratories, INC. | $14.99 | 2025 | Myrisk |
| Seagen INC. | $13.28 | 2023 | Tivdak |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charmaine Grant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.